RGC$32.0
Chart
Performance
Key Stats
AI RGC Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralRegencell Bioscience Holdings Limited shows potential in its niche but faces significant headwinds from its current financial performance and operational status. The stock exhibits volatile technicals, making it a speculative play. Investors should exercise extreme caution due to the lack of revenue and net income.
Thematic
Regencell Bioscience Holdings Limited operates in the promising field of Traditional Chinese Medicine (TCM) for neurocognitive disorders. The growing interest in alternative and holistic treatments for conditions like ADHD and autism spectrum disorder presents a significant thematic tailwind. However, the company's early stage and lack of commercial traction temper the immediate impact of these themes.
Fundamental
Regencell Bioscience Holdings Limited's financials indicate a company in its early stages, with no reported revenue and consistent net losses. The balance sheet shows a significant decrease in assets and cash reserves over the past two years, coupled with substantial negative free cash flow, raising concerns about financial sustainability.
Technical
Regencell Bioscience Holdings Limited's stock exhibits considerable volatility. While some short-term indicators suggest potential upward momentum, the overall trend is weak, and recent price action shows a significant decline from its 52-week high. Trading is currently below key longer-term moving averages.
| Factor | Score |
|---|---|
| Neurocognitive Disorder Treatment | 75 |
| Traditional Chinese Medicine (TCM) Adoption | 70 |
| Biotech R&D and Innovation | 55 |
| Regulatory Environment (Biotech) | 60 |
| Geographic Focus (Hong Kong & Asia) | 65 |
| Factor | Score |
|---|---|
| Valuation | 0 |
| Valuation | 0 |
| Profitability | 0 |
| Growth | 0 |
| Balance Sheet Health | 80 |
| Balance Sheet Health | 95 |
| Cash Flow | 10 |
| Cash Flow | 15 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 50 |
| Momentum | 40 |
| Support & Resistance | 50 |
| Volume | 60 |
| Price Action | 45 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Exceptional Short-Term Performance
The stock has shown remarkable short-term performance, with a 5-day gain of 10.1% and a year-to-date return of 11,765.15%. This indicates significant positive momentum and investor interest.
Focus on Growing Market
Regencell Bioscience Holdings Limited operates in the Traditional Chinese medicine (TCM) sector, focusing on the research, development, and commercialization of TCM for neurocognitive disorders and degeneration, including ADHD and autism spectrum disorder. This targets a potentially growing and underserved market.
Bearish Points (8)
Zero Revenue and Net Losses
The company reported zero revenue for the periods Q2 2024, Q2 2023, Q2 2022, and Q2 2021, coupled with significant net losses. This indicates a lack of commercialization and profitability.
Extremely High Price-to-Sales (P/S) Ratio
Although revenue is zero, the reported P/E ratios are extremely negative (e.g., -1730.0 in Q2 2024) and P/S ratios are zero. This indicates the company is not generating sales, making traditional valuation metrics uninformative and suggesting a speculative valuation based on future potential.
Calendar
July 2025
17
Next Earnings Date
H: $
A: $
L: $
Profile
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. The company focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. Regencell Bioscience Holdings Limited was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Seasonals
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
One of the largest natural gas-only distributors in the U.S., serving multiple states; a direct and highly comparable peer to RGCO's core business.
Weight: 90
Major natural gas utility serving customers across several Western states; highly similar business model and focus on gas distribution.
Weight: 90
A leading natural gas utility operating in the Midwest and Southeast; provides regulated natural gas distribution services, making it a direct peer.
Weight: 88
Diversified energy company with significant natural gas and propane distribution operations, including a large utility segment similar to RGCO.